Skip to content

Integration of multiple omics and phenotypic data for the diagnosis and prognosis of tuberculosis

Integration of multiple omics and phenotypic data for the diagnosis and prognosis of tuberculosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028670
Enrollment
Unknown
Registered
2019-12-29
Start date
2020-01-15
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis

Interventions

Pulmonary Tuberculosis:no
Tuberculous meningitis:no
Disease control (non-PTB):no
Disease control (non-MTB):no

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Cases: 1. Patients with clinically diagnosed tuberculosis (including tuberculosis, bronchial tuberculosis and tuberculous pleurisy, which can be accompanied by extrapulmonary tuberculosis, and the diagnostic criteria are ws288-2017), and the primary treatment; 3. Before receiving anti-tuberculosis treatment, the duration of antibacterial drugs was less than 1 week; Non-cases control group: 1. Acid-fast smear and tuberculosis culture were negative, and tuberculosis infection was excluded after clinical diagnosis; 2. Clinically diagnosed as pulmonary infectious disease or early neoplastic disease; Healthy control group: 1. No history of tuberculosis; negative MTB test including acid-fast staining smear, culture and TB-DNA test; 2. Proved to be a healthy person by physical examination.

Exclusion criteria

Exclusion criteria: 1. HIV, hepatitis B, syphilis, hepatitis C and other infectious diseases; 2. A long history of medication, such as immunosuppressants; 3. Chronic and metabolic diseases, such as diabetes, hypertension, allergic diseases, asthma, obesity, or other end-stage diseases; 4. The researchers determined that the patients were not suitable for inclusion in the trial.

Design outcomes

Primary

MeasureTime frame
outcome of treamtent;adverse drug reactions;RNA expression;Microbial flora ratio;Intestinal metabolite content;

Secondary

MeasureTime frame
smear conversion rate;culture conversion rate;Lesions change;

Countries

China

Contacts

Public ContactBinwu Ying
docbwy@126.com+86 18980601655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026